MicroPort Scientific Corp. Reports 10% Revenue Growth and 58% Net Loss Decrease in 2024
Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) released its 2024 full-year performance estimation....
SonoScape Medical Corp. Wins First AI-Powered Prenatal Ultrasound Approval in China
Shenzhen-based SonoScape Medical Corp. announced receiving marketing approval in China for its S-Fetus prenatal ultrasound...
TYK Medicines Inc.’s TY-9591 Shows Superiority Over Osimertinib in EGFR Mutated Lung Cancer with Brain Metastasis
Zhejiang-based TYK Medicines Inc. (HKG: 2410) announced positive results from a pivotal Phase II study...
Anlong Biopharmaceutical and Sun-Novo Partner to Advance siRNA Technology in Cardiovascular Treatments
On March 10, 2025, Anlong Biopharmaceutical and Sun-Novo Pharmaceutical announced a strategic partnership to advance...
AIM Vaccine Co. Ltd Receives NMPA Approval for Human Diploid Rabies Vaccine Trial
China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced receiving approval from the National Medical...
NewCo Model: China’s Innovative Drug Companies’ New Transaction Mode in Capital Winter
NewCo is a new transaction model developed by Chinese innovative drug companies in response to...
Hangzhou Chance Pharmaceuticals Secures New Funding for Inhalation Powder Aerosol Development
Hangzhou Chance Pharmaceuticals recently announced the completion of a new funding round, led by Zhejiang’s...
Sino Biopharmaceutical Licenses Nanjing Delova’s QP001 for Mainland China Rights
China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced acquiring exclusive rights to Nanjing Delova Biotech Co.,Ltd’s...
Fosun Pharmaceutical’s Foritinib Accepted for Review by China’s NMPA for NSCLC Treatment
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that the National...
Everest Medicines Begins Clinical Trial for Personalized mRNA Cancer Vaccine EVM16
China-based Everest Medicines (HKG: 1952) has announced the first patient dosing of an investigator-initiated clinical...
Sinocelltech Group Receives NMPA Approval for SCTT11 Clinical Study in Thyroid Eye Disease
China-based Sinocelltech Group Ltd (SHA: 688520) has announced receiving approval from the National Medical Products...
Johnson & Johnson Terminate Phase III VENTURA Program for Aticaprant in adjunctive treatment of MDD
US giant Johnson & Johnson (J&J; NYSE: JNJ) announced the termination of the Phase III...
Gan & Lee Pharmaceuticals Joins Brazil’s PDP for Localized Insulin Production
China-based Gan & Lee Pharmaceuticals (SHA: 603087) announced receiving a financial pledge of BRL130 million...
Insilico Medicine’s AI-Discovered Drug Rentosertib Approved for Clinical Trials
China’s generative artificial intelligence (AI)-driven biotech Insilico Medicine announced approval by the United States Adopted...
4C Medical Lands $175M Series D to Advance AltaValve TMVR System
US-based 4C Medical Technologies, Inc., a medical device company controlled by China-based MicroPort CardioFlow Medtech...
Merck KGaA Reports 2024 Revenue Growth Despite Challenges in Life Sciences
German major Merck KGaA (ETR: MRK) this week released its 2024 annual report, highlighting a...
Astellas Pharma and YASKAWA Establish JV for Cell Therapy Product Manufacturing Platform
Japan-based Astellas Pharma Inc. (TYO: 4503) is set to establish a joint venture (JV) with...
Johnson & Johnson Officially Launches Spravato in China for Depression Treatment
US giant Johnson & Johnson (J&J; NYSE: JNJ) officially launched Spravato (esketamine) nasal spray in...
Abbisko Therapeutics’ ABSK131 Receives Clinical Trial Approval from China’s NMPA
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced receiving clinical trial approval from...
Cryofocus Medtech’s Malignant Stenosis Cryoablation System Approved by NMPA for Chinese Market
Shanghai-based cryoablation treatment specialist Cryofocus Medtech (Shanghai) Co., Ltd (HKG: 6922) has announced receiving endorsement...